[PCSK9 inhibitors : Current clinical relevance].

Area of Science:

• Cardiology
• Pharmacology
• Genetics

Background:

• Hypercholesterolemia is a significant risk factor for cardiovascular diseases.
• Existing therapies like statins may not achieve treatment goals for all patients, especially those with very high LDL cholesterol or intolerance.
• There is a need for novel treatment options for high-risk hypercholesterolemia patients.

Purpose of the Study:

• To present the clinical relevance of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for hypercholesterolemia treatment.
• To review available data and German regulations concerning PCSK9 inhibitors.
• To assess the efficacy and safety of PCSK9 inhibitors in managing hypercholesterolemia.

Main Methods:

• Review of clinical data for PCSK9 inhibitors (evolocumab and alirocumab) approved in 2015.
• Analysis of data from diverse patient groups, including those with homozygous familial hypercholesterolemia.
• Examination of long-term data, imaging studies, and regulatory guidelines in Germany.

Main Results:

• PCSK9 inhibitors demonstrate a significant LDL cholesterol reduction of 50-60% with a favorable safety profile.
• Efficacy is noted across various patient groups, though less pronounced in homozygous familial hypercholesterolemia.
• Early long-term data and imaging studies suggest potential for reducing cardiovascular events, pending further trials.

Conclusions:

• The growing body of evidence supports the use of PCSK9 inhibitors in clinical decision-making.
• PCSK9 inhibitors represent a significant advancement in treating high-risk patients with hypercholesterolemia.
• These novel therapies enhance treatment options for achieving optimal lipid management.